Patients with chronic kidney disease face an elevated risk of developing dyslipidemia because of reduced activities of lipoprotein lipase and lecithin cholesterol acyltransferase, along with lower hepatic lipase levels [46]. The gene discussed is LCAT; the disease is metabolic syndrome.